Meeting
2020 ASCO Virtual Scientific Program
Prognostic effect of specific RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC).
Authors
Ben George
Froedtert & The Medical College of Wisconsin, Milwaukee, WI
Ben George , Bradley W Taylor , Matthew Lasowski , Paul S. Ritch , Aditya Varnam Shreenivas , Sakti Chakrabarti , Mandana Kamgar , Michael T Zimmermann , Honey V Reddi , Raul Urrutia , James P. Thomas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4050)
DOI
10.1200/JCO.2020.38.15_suppl.4050
Abstract #
4050
Poster Bd #
42
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Haisam Abid
Poster
2018 Gastrointestinal Cancers Symposium
Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).
First Author: Ben George
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.
First Author: Anastasia Danilova
Poster
2023 ASCO Annual Meeting
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).
First Author: Nicola Normanno